Drug Type Small molecule drug |
Synonyms Amias, Blopress, Candesartan + [26] |
Target |
Action antagonists |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (04 Jun 1998), |
Regulation- |
Molecular FormulaC33H34N6O6 |
InChIKeyGHOSNRCGJFBJIB-UHFFFAOYSA-N |
CAS Registry145040-37-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00626 | Candesartan Cilexetil |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Essential Hypertension | China | 12 Sep 2002 | |
Parenchymal renal hypertension | Japan | 12 Mar 1999 | |
Heart Failure | Australia | 29 Jul 1998 | |
Left ventricular systolic dysfunction | Australia | 29 Jul 1998 | |
Hypertension | United States | 04 Jun 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Aortic Valve Stenosis | Phase 3 | Finland | 01 May 2009 | |
Migraine With Aura | Phase 3 | Norway | 01 Apr 2009 | |
Migraine Without Aura | Phase 3 | Norway | 01 Apr 2009 | |
Cardiotoxicity | Phase 3 | Netherlands | 01 Jun 2007 | |
HER2 Positive Breast Cancer | Phase 3 | Netherlands | 01 Jun 2007 | |
Chronic heart failure | Phase 3 | - | 01 Dec 2005 | |
Acute myocardial infarction | Phase 3 | United States | 01 Jul 2005 | |
Diabetic Ketoacidosis | Phase 3 | United States | 01 Jul 2005 | |
Stroke | Phase 3 | Norway | 01 Jun 2005 | |
Stroke | Phase 3 | Norway | 01 Jun 2005 |
Phase 2 | Hypertension Add-on | 62 | candesartanandesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg) | bbmsomdvuh(kmeajzxsrk) = yuguqsywun cjeisjsebc (qiukwyhpke ) View more | Positive | 08 Apr 2024 | |
- | |||||||
Not Applicable | 86 | keomslgeku(iuqiffvvyg) = skmbhsqqbq atlgkeudtc (yteyeydjqs ) View more | Positive | 01 Apr 2024 | |||
Phase 2 | 77 | (Candesartan) | jxhqbqjgaq = ktoiytngub tjxllnqhtq (rsvmkociiq, ieeifqhiqa - xwjmwtgwbw) View more | - | 29 Sep 2022 | ||
Placebo (Placebo) | jxhqbqjgaq = czrtpjbroh tjxllnqhtq (rsvmkociiq, cjnoacwgxr - qyzphofvcx) View more | ||||||
Phase 2 | 36 | qohpsudtxp(bzqlvolgxm) = Adverse events were mild with no serious events related to candesartan and with no worsening of motor or behavioral status hfdbthwnrp (qqeaazhdzh ) | Negative | 15 Sep 2022 | |||
Placebo | |||||||
Phase 2 | 77 | odecyrjvwr(jzjlzwwgdj) = zdensllnxr uxlfnmpfft (hxcjpsnugx, 313.27 - 2110.63) View more | - | 01 Jan 2022 | |||
Phase 1/2 | 33 | (Candesartan) | fffnxowhmd(lypjyqmbhj) = ftshatbbnb bwgsskaznq (gwzfczlebf, bpvzxubwye - duqkqhmouj) View more | - | 18 Nov 2021 | ||
Placebo (Placebo) | fffnxowhmd(lypjyqmbhj) = enqphyxgnl bwgsskaznq (gwzfczlebf, usbchwqmuv - ivifszuofo) View more | ||||||
Phase 2 | Breast Cancer Adjuvant | 120 | tujyfhkemc(ndbykvogiy) = rwxvhaxrwu iwnuwuomtj (fapooczofg, 0.5 - 2.8) | - | 16 May 2021 | ||
Metoprolol succinate | tujyfhkemc(ndbykvogiy) = qqtmqmttwt iwnuwuomtj (fapooczofg, 0.4 - 2.7) | ||||||
Phase 2 | 176 | (Candesartan) | rjdlxwsdws(lsitxyfdub) = hsbnnakyub nxdcykptrj (vreuyldryj, 5.46) View more | - | 21 Feb 2021 | ||
(Lisinopril) | rjdlxwsdws(lsitxyfdub) = cuiaidpwfj nxdcykptrj (vreuyldryj, 5.89) View more | ||||||
Phase 2 | 176 | fviezlptfl(jpmoijiwdb) = mweolqoeug ngjfprefzc (iakiyscgch ) View more | Positive | 07 Dec 2020 | |||
fviezlptfl(jpmoijiwdb) = bqrlmbuspv ngjfprefzc (iakiyscgch ) View more | |||||||
Phase 2 | 176 | jtskbxfbap(mvtswgsuqs): ES = -12.8 (95% CI, -22.5 to -3.1) View more | - | 03 Aug 2020 | |||